1h Free Analyst Time
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 9 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22219TDB, outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR). The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Dermatology, Immunology and Respiratory which include indications Triple-Negative Breast Cancer (TNBC), Actinic (Solar) Keratosis, Arrhythmias, Asthma, Cervical Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastrointestinal Tumor, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Lung Cancer, Malignant Glioma, Medulloblastoma, Myocardial Infarction, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Skin Cancer and Solid Tumor.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Overview
- Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
- Athenex Inc
- Nuvectis Pharma Inc
- Pulmatrix Inc
- Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Drug Profiles
- KX-2361 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NXP-900 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PP-1 - Drug Profile
- Product Description
- Mechanism Of Action
- PUR-1800 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit C Src Kinase for Colon Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CSK for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- tirbanibulin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- UM-164 - Drug Profile
- Product Description
- Mechanism Of Action
- Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Dormant Products
- Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Discontinued Products
- Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Product Development Milestones
- Featured News & Press Releases
- Oct 18, 2022: Nuvectis Phrama announces poster presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
- Aug 18, 2022: Almirall's Klisyri (tirbanibulin) receives strong recommendation in American Academy of Dermatology AK guideline update
- Jun 22, 2022: Athenex announces sale of revenues from U.S. and European Royalty and Milestone Interests in Klisyri (tirbanibulin) to Sagard Healthcare partners and Oaktree
- Apr 13, 2022: Nuvectis Pharma recaps Poster Presentation highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
- Mar 21, 2022: Pulmatrix announces positive top-line data evaluating PUR1800 in Patients with Stable COPD
- Mar 10, 2022: Nuvectis announces upcoming oral and poster presentations at the 2022 American Association for Cancer Research Meeting
- Feb 22, 2022: Nuvectis announces positive data for NXP900 in triple negative breast cancer preclinical models with an Integrin-Linked Kinase (ILK) Loss
- Sep 27, 2021: Almirall launches Klisyri(Tirbanibulin) for the treatment of actinic keratosis in Europe
- Jul 19, 2021: Almirall receives European Commission approval of Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
- May 21, 2021: Almirall receives positive CHMP opinion for Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
- Apr 12, 2021: Pulmatrix to regain full rights to PUR1800 and narrow spectrum kinase inhibitor portfolio
- Mar 04, 2021: Pulmatrix provides update on its lung cancer drug candidate PUR-1800
- Feb 18, 2021: Almirall U.S. launches Klisyri (tirbanibulin), a new, innovative topical treatment for actinic keratosis
- Feb 18, 2021: Athenex announces U.S. launch of Klisyri and licensing of additional territories for tirbanibulin
- Feb 11, 2021: Athenex announces New England Journal of Medicine publication of phase III data on the efficacy and safety of Klisyri (tirbanibulin)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Athenex Inc, 2022
- Pipeline by Nuvectis Pharma Inc, 2022
- Pipeline by Pulmatrix Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Athenex Inc
- Nuvectis Pharma Inc
- Pulmatrix Inc
